← Back
September 1, 2020

Research coaction

As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.

We have now initiated a collaboration with Prof. Pradhan who is a world leader in delta opioid neurobiology with a particular interest in migraine and with Prof. Eamonn Kelly (University of Bristol) our existing research partner and opioid expert with the intention of applying for NIH funding to synthesize and test a range of new DORA structures. The aim is to develop new compounds for treating migraine and other headaches.

Success could lead to new patents following up on our lead compound PN6047 and entry into the large international migraine/headache market.


David Kendall

Patent granted in China

We are pleased to announce that PharmNovo AB has been granted a patent for our candidate PN6047 in China. PharmNovo AB is currently entering into regulatory toxicology studies with PN6047 – an exciting phase in the development of this biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins. In preclinical testing, our candidate effectively reduces neuropathic pain without any of the unwanted side effects of conventional opioids.

Read more →

New board member

PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.

Read more →

22 MSEK new funding

PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.

Read more →

New CEO appointed

The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.

Read more →

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden